Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

435P - Bevacizumab (bev) continuation with FOLFIRI or switch to aflibercept (afli) with FOLFIRI as second-line treatment (L2) after first line of FOLFOX-bev (L1) for metastatic colorectal cancer (mCRC): An AGEO multicenter study

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Colon and Rectal Cancer

Presenters

Cecile Torregrosa

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

C. Torregrosa1, S. Pernot2, A. Perret3, V. Randrian4, S. Racine Doat5, B. Auberger6, T. Godet7, M. Jaffrelot8, O. Dubreuil9, A. Turpin10, L. Palmieri11, O. Bouche12, T. Lecomte13, D. Sefrioui14, C. Locher15, C. Neuzillet16, E. Nassif17, C. Lecaille18, J. Taieb1, E. Auclin1

Author affiliations

  • 1 Gastroenterology And Digestive Oncology Department, Hopital European George Pompidou, 75015 - Paris/FR
  • 2 Oncology Department, Bergonie Institute, bordeaux/FR
  • 3 Department Of Cancer Medicine, Gustave Roussy Cancer Institute, Villejuif/FR
  • 4 Hepatology And Gastro-enterology Department, University Hospital Center of Poitiers, Poitiers/FR
  • 5 Oncology Department, AP-HP Hôpital Universitaire Pitié Salpêtrière - Charles Foix, 75013 - Paris/FR
  • 6 Oncology Department, University Hospital Center of Brest, Brest/FR
  • 7 Gastroenterology And Digestive Oncology Department, University Hospital Center of Angers, Angers/FR
  • 8 Haute Garonne, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 9 Oncology Department, Diaconesses - Croix Saint Simon Hospital, Paris/FR
  • 10 Oncology Department, Hopital Claude Huriez, 59037 - Lille/FR
  • 11 Gastroenterology And Digestive Oncology Department, University Hospital Center of Cochin, Assistance Publique des Hôpitaux de Paris, Paris/FR
  • 12 Oncology Department, CHU de Reims - Hôpital Robert Debré, 51092 - Reims/FR
  • 13 Department Of Hepato-gastroenterology And Digestive Oncology, CHU de Tours, Hôpital Trousseau, 37170 - Chambray-lès-Tours/FR
  • 14 Normandie University, Inserm 1245, Digestive Oncology Unit, Hepatogastroenterology Department, Rouen university Hospital, 76031 - Rouen/FR
  • 15 Gastroenterology And Digestive Oncology Department, Meaux Hospital, Meaux/FR
  • 16 Oncology Department, Curie Institute, 92210 - Saint cloud/FR
  • 17 Oncology Department, Leon Berard Institute, Lyon/FR
  • 18 Gastroenterology Department, Polyclinique Nord Aquitaine, bordeaux/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 435P

Background

The continuation of angiogenesis inhibition increases survival compared to FOLFIRI alone after failure of L1 for mCRC but no study has evaluated the direct comparison between bev continuation and the switch to afli.

Methods

In this French retrospective multicentre cohort, we included patients with mCRC treated with either FOLFIRI-afli or FOLFIRI-bev at the oncologist’s discretion after progression on L1. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR+PR+SD) and safety. We also analysed PFS in a subgroup of primary bev-resistant patients (L1 PFS<3 months).

Results

A total of 346 patients from 17 centres were included: 165 in the afli group and 181 in the bev group. No significant difference in patient characteristics was observed (including for L1 PFS < 3 months). Median age was 63.5 years and 53.8% of patients were men. Most patients had RAS-mutated tumours (76.3%), synchronous metastatic disease (87%), and an ECOG performance status (PS) 0-1 (82.4%). After a median follow up of 27.3 months, median OS was 13.8 months (95%CI: 11.2-15.4) and 9.7 months (95%CI: 7.7-11.9) in the bev and afli groups, respectively (P<0.0001). Median PFS was 5.5 months and 4.7 months, respectively (P<0.01). DCR in the bev and afli groups were 72.7% and 61.8% (P=0.04). After adjustment for age, PS, CEA level, L1 PFS, primary tumour resection, metastases location and RAS/BRAF status, bev was associated with better OS (HR: 0.67, 95%CI: 0.49-0.92, P=0.01) and PFS (HR: 0.70, 95%CI: 0.54-0.90, P=0.005). In the primary bev-resistant group, no difference was observed between bev and afli: OS (median: 8.0 vs 9.3 months, P=0.3) and PFS (median: 6.5 vs 5.0 months, P=0.4). Grade 3-4 toxicities were more frequent in the afli group: asthenia (24.8% vs 12.7%, P=0.004), diarrhoea (16.4% vs 6%, P=0.002), and hypertension (9.7% vs 3.9%, P=0.03).

Conclusions

In this large multicentre retrospective cohort, FOLFIRI-bev was associated with longer PFS and OS as compared to FOLFIRI-afli in patients with mCRC in L2 after progression on FOLFOX-bev. A prospective study is warranted to confirm these results.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Cecile Torregrosa.

Funding

Has not received any funding.

Disclosure

S. Pernot: Honoraria (self): Amgen; Honoraria (self): Merck; Honoraria (self): Pierre Fabre; Honoraria (self): Sanofi; Honoraria (self): Servier. O. Dubreuil: Travel/Accommodation/Expenses: Sanofi; Travel/Accommodation/Expenses: Roche. A. Turpin: Honoraria (self): Amgen; Honoraria (self): Merck; Honoraria (self): Servier; Honoraria (self): Mylan; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Sanofi. L-J. Palmieri: Honoraria (self): Amgen; Honoraria (self): Merck; Honoraria (self): Servier; Honoraria (self): Keocyt. O. Bouche: Honoraria (self): Merck KGaA; Honoraria (self): Pierre Fabre; Honoraria (self): Servier; Honoraria (self): Amgen; Honoraria (self): MSD; Honoraria (self): Grunenthal; Honoraria (self): AstraZeneca; Honoraria (self): Bayer; Honoraria (self): Roche Genentech. D. Sefrioui: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Travel/Accommodation/Expenses: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses: Servier; Travel/Accommodation/Expenses: Novartis; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Sandoz; Travel/Accommodation/Expenses: Pierre Fabre. C. Locher: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: Ipsen; Honoraria (self): Merck; Honoraria (self): Novartis. C. Lecaille: Honoraria (self), Travel/Accommodation/Expenses: Sanofi; Honoraria (self), Travel/Accommodation/Expenses: Roche. J. Taieb: Advisory/Consultancy: Roche; Advisory/Consultancy: Genetech; Advisory/Consultancy: Lilly; Advisory/Consultancy: Servier; Advisory/Consultancy: Sanofi; Advisory/Consultancy: Celgene; Advisory/Consultancy: Shire; Advisory/Consultancy: Amgen; Advisory/Consultancy: Sirtex; Advisory/Consultancy: Merck; Advisory/Consultancy: MSD. E. Auclin: Honoraria (self): Sanofi; Honoraria (self): Genzymes. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.